These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 33387727

  • 21. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M, Afatinib Compassionate Use Consortium (ACUC).
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [Abstract] [Full Text] [Related]

  • 22. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
    Tanaka H, Taima K, Itoga M, Ishioka Y, Baba K, Shiratori T, Sakamoto H, Tsuchiya J, Nakagawa H, Hasegawa Y, Yasugahira H, Okudera K, Takanashi S, Tasaka S.
    Med Oncol; 2019 May 14; 36(6):57. PubMed ID: 31089973
    [Abstract] [Full Text] [Related]

  • 23. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
    Imai H, Kaira K, Suzuki K, Anzai M, Tsuda T, Ishizuka T, Kuwako T, Naruse I, Nemoto K, Uchino J, Morozumi N, Ishihara S, Minato K, Hisada T.
    Lung Cancer; 2018 Dec 14; 126():41-47. PubMed ID: 30527191
    [Abstract] [Full Text] [Related]

  • 24. A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
    van Veggel BAMH, van der Wekken AJ, Paats MS, Hendriks LEL, Hashemi SMS, Daletzakis A, van den Broek D, Bosch LJW, Monkhorst K, Smit EF, de Langen AJ.
    Cancer; 2024 Mar 01; 130(5):683-691. PubMed ID: 37905752
    [Abstract] [Full Text] [Related]

  • 25. Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
    Fan Y, Chen J, Zhou C, Wang H, Shu Y, Zhang J, Hua H, Huang DC, Zhou C.
    Lung Cancer; 2020 Sep 01; 147():209-213. PubMed ID: 32738416
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
    Shi Y, Li B, Wu L, Pan Y, Pan Z, Liu Y, Fan Y, Ji Y, Fang J, Shi Q, Shi J, Gao H, Hu Y, Wang X, He Z, Ma R, Zhang Y, Jiang D, Bai Y, Zhang Y, Huang L, Zhou T, Liu H, Wang D, Wen Q, Chen G, Zang A, Wang X, Zhang X, Hu J, Yang R, Zhang G, Gu K, Wang L, Wang Q, Wei Z, Li Z, Lu H, Zhang H, Chen H, Song T.
    J Thorac Oncol; 2022 Oct 01; 17(10):1205-1215. PubMed ID: 35659581
    [Abstract] [Full Text] [Related]

  • 27. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
    Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K.
    Cancer Chemother Pharmacol; 2018 Dec 01; 82(6):1031-1038. PubMed ID: 30276451
    [Abstract] [Full Text] [Related]

  • 28. A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.
    Park JS, Hong MH, Chun YJ, Kim HR, Cho BC.
    Lung Cancer; 2019 Aug 01; 134():46-51. PubMed ID: 31319994
    [Abstract] [Full Text] [Related]

  • 29. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ.
    Eur J Cancer; 2019 Sep 01; 119():77-86. PubMed ID: 31425965
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH, Leung DK, Choy TS, Lam KO, Lam PM, Leung TW, Kwong DL.
    BMC Cancer; 2016 Feb 24; 16():147. PubMed ID: 26911310
    [Abstract] [Full Text] [Related]

  • 32. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.
    Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC.
    Lung Cancer; 2019 Jul 24; 133():10-19. PubMed ID: 31200814
    [Abstract] [Full Text] [Related]

  • 33. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.
    Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW.
    BMC Cancer; 2021 Jul 27; 21(1):859. PubMed ID: 34315431
    [Abstract] [Full Text] [Related]

  • 34. A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
    Pham CP, Nguyen TTH, Do AT, Nguyen TK, Hoang TAT, Le TA, Vuong DTH, Nguyen DNT, Dang VK, Nguyen TO, Pham VL, Nguyen MH, Vo THT, Do HK, Vu HT, Nguyen TTH, Pham VT, Trinh LH, Nguyen KD, Nguyen HG, Truong CM, Pham TMC, Nguyen TBP.
    BMC Cancer; 2024 Feb 05; 24(1):176. PubMed ID: 38317094
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group.
    Sonehara K, Kobayashi T, Tateishi K, Morozumi N, Yoshiike F, Hachiya T, Ono Y, Takasuna K, Agatsuma T, Masubuchi T, Matsuo A, Tanaka H, Morikawa A, Hanaoka M, Koizumi T.
    Thorac Cancer; 2019 May 05; 10(5):1078-1085. PubMed ID: 31006178
    [Abstract] [Full Text] [Related]

  • 38. Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib.
    Tamura K, Nukiwa T, Gemma A, Yamamoto N, Mizushima M, Ochai K, Ikeda R, Azuma H, Nakanishi Y.
    Int J Clin Oncol; 2019 Aug 05; 24(8):917-926. PubMed ID: 30953238
    [Abstract] [Full Text] [Related]

  • 39. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    Tan WL, Ng QS, Lim C, Tan EH, Toh CK, Ang MK, Kanesvaran R, Jain A, Tan DSW, Lim DW.
    BMC Cancer; 2018 Dec 03; 18(1):1198. PubMed ID: 30509246
    [Abstract] [Full Text] [Related]

  • 40. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
    Kim MH, Choi CM, Lee SY, Park CK, Chang YS, Lee KY, Kim SJ, Yang SH, Ryu JS, Lee JE, Lee SY, Park CK, Lee SH, Jang SH, Yoon SH, Jang TW.
    Anticancer Res; 2022 Mar 03; 42(3):1615-1622. PubMed ID: 35220259
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.